Stephen Liu: AstraZeneca Reaches Deal with Dizal to Bring Sunvozertinib to the US!

oncodaily - Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X: “FINALLY! AstraZeneca reaches deal with Dizal […]

AI Summary: AstraZeneca reached a deal to make sunvozertinib available in the U.S., accelerating global access for patients with EGFR exon 20 insertion–positive non–small cell lung cancer. The move follows encouraging WU-KONG1B data and signals commercial partnerships are finally translating niche trial gains into real-world treatment options for a stubbornly underserved subgroup.

• AstraZeneca-Dizal deal opens US access to sunvozertinib (3)
• Testing, treatment gaps and rising rare-NSCLC approvals (3)
• WU-KONG1B confirms sunvozertinib activity in EGFR Exon20 (3)

AstraZeneca-Dizal deal opens US access to sunvozertinib

Testing, treatment gaps and rising rare-NSCLC approvals

WU-KONG1B confirms sunvozertinib activity in EGFR Exon20